Research location
Ventspils
Latvia
Advertisement
Research activity in Ventspils
LatviaCureCurrent currently publishes aggregate city-level research activity for this location: 18 trials and 18 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Ventspils
18 linked trials · page 1 of 1EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation
RECRUITING
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%NCT04435626 · 2020-09-14 · 1 site observation
COMPLETED
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 1 site observation
COMPLETED
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection FractionNCT02226120 · 2014-10-16 · 1 site observation
COMPLETED
Phenotypes of COPD in Central and Eastern EuropeNCT02119494 · 2014-06-01 · 1 site observation
COMPLETED
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge PatientsNCT02111564 · 2014-01-07 · 1 site observation
COMPLETED
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart FailureNCT01877915 · 2013-09-10 · 1 site observation
COMPLETED
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus MethotrexateNCT01764997 · 2013-04-01 · 1 site observation
TERMINATED
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes MellitusNCT01683266 · 2012-09-01 · 1 site observation
COMPLETED
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic TherapyNCT01676220 · 2012-08-01 · 1 site observation
COMPLETED
Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney DiseaseNCT01309828 · 2011-03-01 · 1 site observation
COMPLETED
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation
COMPLETED
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma INCT01172808 · 2010-08-01 · 1 site observation
COMPLETED
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart FailureNCT01035255 · 2009-12-01 · 1 site observation
TERMINATED
Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in HypertensionNCT00923091 · 2009-06-01 · 1 site observation
COMPLETED
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic BronchitisNCT00656747 · 2008-03-01 · 1 site observation
COMPLETED
Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.NCT00563381 · 2008-01-01 · 1 site observation
COMPLETED
NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single InhalerNCT00557297 · 2007-10-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.